Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Givastomig - NovaBridge Biosciences

Next Previous
Drug Profile

Givastomig - NovaBridge Biosciences

Alternative Names: ABL-111; CD4B; Giva; TJ-033721; TJ-CD4B; TJ-CLDN4B

Latest Information Update: 03 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator I-MAB Biopharma
  • Developer NovaBridge Biosciences
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Adenocarcinoma; Gastric cancer
  • Phase I Pancreatic cancer; Solid tumours
  • No development reported Colorectal cancer

Most Recent Events

  • 25 Feb 2026 Phase-II clinical trials in Adenocarcinoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Treatment-naive, Combination therapy) in USA (IV) (NCT07432295)
  • 18 Feb 2026 Phase-II clinical trials in Gastric cancer (First-line therapy, Combination therapy, Metastatic disease) (Parenteral)
  • 06 Jan 2026 Updated adverse events and efficacy data from a phase I trial in Gastric cancer released byNovaBridge Biosciences

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top